Current Diabetes Reports

, 15:87 | Cite as

Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: What Have We Learned? An Industry Perspective

  • Boaz Hirshberg
  • Arie Katz
Macrovascular Complications in Diabetes (VR Aroda and A Getaneh, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Macrovascular Complications in Diabetes


Owing to the close association of cardiovascular (CV) disease with type 2 diabetes and the uncertainty surrounding the CV safety of antidiabetes agents, in 2008 the Food and Drug Administration issued guidance for the demonstration of CV safety for new antidiabetes drugs. Recently the results from CV outcomes trials of three dipeptidyl peptidase-4 (DPP-4) inhibitors and a glucagon-like peptide-1 receptor agonist have been reported. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial, the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE) trial, and the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) assessed the safety of saxagliptin, alogliptin, and sitagliptin, respectively, in patients with type 2 diabetes with CV disease or at high risk for CV disease. The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) assessed the safety of lixisenatide in patients with type 2 diabetes and a recent acute coronary syndrome event. The results show that these agents neither increased nor deceased major adverse CV events (CV death, nonfatal myocardial infarction, and nonfatal stroke) compared with placebo. However, the resources needed to conduct these studies may detract from the ability to understand the potential long-term benefit and risk in the majority of patients that are candidates for use of these medications.


Alogliptin Antidiabetes drugs Cardiovascular safety DPP-4 inhibitors Saxagliptin Sitagliptin 



Medical writing support for the preparation of this manuscript was provided by Richard Edwards, PhD, and Janet Matsuura, PhD, from Complete Healthcare Communications, Inc. (Chadds Ford, PA), with funding from AstraZeneca.

Compliance with Ethics Guidelines

Conflict of Interest

Boaz Hirshberg is an employee of MedImmune, LLC, a wholly owned subsidiary of AstraZeneca.

Arie Katz is an employee of AstraZeneca.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. 2014. Accessed June 11 2015.
  2. 2.
    Preis SR, Pencina MJ, Hwang SJ, D'Agostino Sr RB, Savage PJ, Levy D, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009;120(3):212–20.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Collaboration ERF, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.CrossRefGoogle Scholar
  4. 4.
    Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Blind E, Dunder K, de Graeff PA, Abadie E. Rosiglitazone: a European regulatory perspective. Diabetologia. 2011;54(2):213–8.CrossRefPubMedGoogle Scholar
  7. 7.•
    Food and Drug Administration. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Center for Drug Evaluation and Research. 2008. Accessed June 11 2015. Document discusses recommendations for assessing cardiovascular risk of new antidiabetes drugs.
  8. 8.
    European Medicines Agency. Guidelines on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012. Accessed June 11 2015.
  9. 9.
    Hirshberg B, Katz A. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care. 2013;36 Suppl 2:S253–8.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Zannad F, Stough WG, Pocock SJ, Sleight P, Cushman WC, Cleland JG, et al. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? Eur Heart J. 2012;33(9):1049–57.CrossRefPubMedGoogle Scholar
  11. 11.
    Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27.CrossRefPubMedGoogle Scholar
  12. 12.
    Iqbal N, Parker A, Frederich R, Donovan M, Hirshberg B. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014;13:33.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12:485–94.CrossRefPubMedGoogle Scholar
  14. 14.
    Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3. doi: 10.1186/1475-2840-11-3.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(7):668–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Marso SP, Lindsey JB, Stolker JM, House JA, Martinez Ravn G, Kennedy KF, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8(3):237–40.CrossRefPubMedGoogle Scholar
  21. 21.
    Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(1):38–47.CrossRefPubMedGoogle Scholar
  22. 22.
    Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383(9933):2008–17.CrossRefPubMedGoogle Scholar
  23. 23.••
    Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. Cardiovascular outcomes trial of saxagliptin.CrossRefPubMedGoogle Scholar
  24. 24.
    Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(4):696–705. doi: 10.2337/dc14-1850.PubMedGoogle Scholar
  25. 25.
    Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38(6):1145–53.CrossRefPubMedGoogle Scholar
  26. 26.
    Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88.CrossRefPubMedGoogle Scholar
  27. 27.••
    White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. Cardiovascular outcomes trial of alogliptin.CrossRefPubMedGoogle Scholar
  28. 28.
    Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76.CrossRefPubMedGoogle Scholar
  29. 29.••
    Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015. Cardiovascular outcomes trial of sitagliptin. Google Scholar
  30. 30.
    Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with ave0010 (lixisenatide) (ELIXA). 2015. Accessed June 30 2015.
  31. 31.••
    No cv benefit with lixisenatide in ELIXA, but results reassure., Medscape. Accessed June 30 2015. Cardiovascular outcomes trial of lixisenatide.
  32. 32.
    Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–97.CrossRefPubMedGoogle Scholar
  33. 33.
    Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3(5):356–66.CrossRefPubMedGoogle Scholar
  34. 34.
    Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147–58.CrossRefPubMedGoogle Scholar
  35. 35.
    Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 2014;2(6):573–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Fu AZ, Johnston S, Sheehan J, Ghannam A, Tsai K, Cappell K, et al. Risk of hospitilization for heart failure with dipeptidyl petidase-4 inhibitors vs sulfonylureas and with saxaagliptin vs sitagliptin in a US claims database. Diabetes. 2015;64(Suppl 1A):LB42.Google Scholar
  37. 37.
    Giorda CB, Picariello R, Tartaglino B, Marafetti L, Di Noi F, Alessiato A, et al. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case–control study. BMJ Open. 2015;5(6), e007959.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Krum H, Skiba M, Wu S, Hopper I. Heart failure and dipeptidyl peptidase-4 inhibitors. Eur J Heart Fail. 2014;16(6):603–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefPubMedGoogle Scholar
  40. 40.
    Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMedGoogle Scholar
  41. 41.
    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.CrossRefPubMedGoogle Scholar
  42. 42.
    Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–206.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.MedImmune, LLCGaithersburgUSA
  2. 2.AstraZenecaFort WashingtonUSA

Personalised recommendations